TBPH - テラバンス・バイオファ―マ (Theravance Biopharma Inc.)

TBPHのニュース

   Acute Lung Injury Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Altor BioScience, Apeiron Biologics, Theravance Biopharma, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals  2021/05/18 01:22:01 AB Newswire
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $39.00 at SVB Leerink  2021/05/12 11:42:46 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective lowered by SVB Leerink from $40.00 to $39.00 in a research report sent to investors on Tuesday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates for Theravance Biopharmas Q2 2021 earnings at ($0.78) EPS, Q3 2021 []
   Head-To-Head Contrast: Spotlight Innovation (OTCMKTS:STLT) vs. Theravance Biopharma (NASDAQ:TBPH)  2021/05/12 01:06:44 Dakota Financial News
Spotlight Innovation (OTCMKTS:STLT) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 80.4% of Theravance Biopharma shares are owned by institutional investors. 5.9% []
   Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of Buy from Analysts  2021/05/11 20:20:41 Transcript Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned a consensus recommendation of Buy from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage []
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $32.00 at Needham & Company LLC  2021/05/11 14:06:41 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective reduced by investment analysts at Needham & Company LLC from $40.00 to $32.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Needham & Company LLCs price target would indicate a potential upside of 66.75% []
   20 Short Ideas With Super-Weak Momentum  2021/05/31 14:39:53 Seeking Alpha
   Theravance Biopharma to Participate in an Upcoming Investor Conference  2021/03/02 11:00:00 PR Newswire
DUBLIN, March 2, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in a pre-recorded Fireside Chat at the H.C….
   Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update  2021/02/23 21:05:00 PR Newswire
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2020. "2020 was a critical year of growth for YUPELRI, with our commercial…
   The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings  2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.
   Theravance Biopharma to Participate in Upcoming Investor Conferences  2021/02/10 11:00:00 PR Newswire UK
DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Management will be…
   Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021  2021/02/09 11:00:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2020 financial results…

calendar